Please use this identifier to cite or link to this item:
Title: Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
Austin Authors: Wang, Mengzhao;Yang, James Chih-Hsin;Mitchell, Paul L R ;Fang, Jian;Camidge, D Ross;Nian, Weiqi;Chiu, Chao-Hua;Zhou, Jianying;Zhao, Yanqiu;Su, Wu-Chou;Yang, Tsung-Ying;Zhu, Viola W;Millward, Michael;Fan, Yun;Huang, Wen-Tsung;Cheng, Ying;Jiang, Liyan;Brungs, Daniel;Bazhenova, Lyudmila;Lee, Chee Khoon;Gao, Bo;Xu, Yan;Hsu, Wei-Hsun;Zheng, Li;Janne, Pasi A
Affiliation: Austin Health
Westmead Hospital, Australia
Sir Charles Gairdner Hospital, Perth, WA, Australia
Medical Day Care Centre, Australia
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
University of Sydney, Sydney, New South Wales, Australia
National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan
Peking University Cancer Hospital and Institute, Beijing, China
University of Colorado Cancer Center, Aurora, Colorado, United States
Chongqing University Cancer Hospital, chongqing, China
Taipei Veterans General Hospital, Taipei, Taiwan
First Affiliated Hospital Zhejiang University, Hangzhou, China
Affiliated Cancer Hospital of Zhengzhou University, China
National Cheng Kung University Hospital, Tainan, Taiwan
National Yang Ming University, Taipei, Taiwan, Taiwan
University of California, Irvine, Orange, CA, United States
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
ChiMei medical center, liouying, Tainan, Taiwan
Jilin Provincial Cancer Hospital, Changchun, China
Shanghai Chest Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China
UC San Diego Moores Cancer Center, La Jolla, CA, United States
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
National Taiwan University Hospital, Taipei, Taiwan
Dizal pharmaceuticals, Shanghai, China
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Issue Date: 6-Jul-2022
Date: 2022
Publication information: Cancer Discovery 2022; 12(7): 1676-1689
Abstract: Epidermal growth factor receptor exon 20 insertion mutations (EGFR exon20ins) are detected in approximately 2% of patients with non-small cell lung cancer (NSCLC). Due to lack of effective therapy, the prognosis of these patients was poor. Sunvozertinib (DZD9008) was designed as an oral, potent, irreversible and selective EGFR tyrosine kinase inhibitor, showing activity against EGFR exon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase 1 clinical studies, sunvozertinib was tolerated up to 400 mg once daily. The most common drug-related adverse events included diarrhea and skin rash. Antitumor efficacy was observed at the doses of 100 mg and above in patients with EGFR exon20ins NSCLC across different subtypes, with prior amivantamab treatment as well as with baseline brain metastasis. The median duration of response (DoR) has not been reached.
DOI: 10.1158/2159-8290.CD-21-1615
ORCID: 0000-0002-9313-3253
Journal: Cancer Discovery
PubMed URL: 35404393
PubMed URL:
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Sep 26, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.